Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1946-1952

  Didier, Jean Philippe ^a   Villet, Régis ^a,b   Huggler, Elzbieta ^a   Lew, Daniel P ^a   Hooper, David C ^b   Kelley, William L ^a   Vaudaux, Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMINO ACID; CIPROFLOXACIN; RIFAMPICIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIUM CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA REPAIR; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENETIC DAMAGE; GENETIC VARIABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; STAPHYLOCOCCUS AUREUS;

EID: 79955534081     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01407-10     Document Type: Article

References (45)

1. Al Obeid, S., Q. Haddad, A. Cherkaoui, J. Schrenzel, and P. Francois. 2010. First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. J. Clin. Microbiol. 48:2199-2204.
2. Anderson, K. L., et al. 2006. Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. J. Bacteriol. 188:6739-6756. (Pubitemid 44497886)
3. Aubry-Damon, H., C. J. Soussy, and P. Courvalin. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590-2594.
4. Besier, S., et al. 2008. The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189.
5. Billington, O. J., T. D. McHugh, and S. H. Gillespie. 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:1866-1869.
6. Bisognano, C., et al. 2004. A RecA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus. J. Biol. Chem. 279:9064-9071.
7. Campbell, E. A., et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. (Pubitemid 32289282)
8. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:137-145.
9. Cirz, R. T., et al. 2007. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J. Bacteriol. 189:531-539. (Pubitemid 46106385)
10. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Cox, M. M. 1998. A broadening view of recombinational DNA repair in bacteria. Genes Cells 3:65-78. (Pubitemid 28383636)
12. Cox, M. M., et al. 2000. The importance of repairing stalled replication forks. Nature 404:37-41. (Pubitemid 30143124)
13. Drlica, K., M. Malik, R. J. Kerns, and X. Zhao. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
14. Erill, I., S. Campoy, and J. Barbe. 2007. Aeons of distress: an evolutionary perspective on the bacterial SOS response. FEMS Microbiol. Rev. 31:637-656.
15. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
16. Ferrero, L., et al. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
17. Goerke, C., J. Koller, and C. Wolz. 2006. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:171-177.
18. Halpern, D., et al. 2007. Identification of DNA motifs implicated in maintenance of bacterial core genomes by predictive modeling. PLoS Genet. 3:1614-1621. (Pubitemid 47510255)
19. Kelley, W. L. 2006. Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon. Mol. Microbiol. 62:1228-1238.
20. Kunkel, T. A., and D. A. Erie. 2005. DNA mismatch repair. Annu. Rev. Biochem. 74:681-710.
21. Kuzminov, A. 1995. Collapse and repair of replication forks in Escherichia coli. Mol. Microbiol. 16:373-384.
22. Li, D., et al. 2005. Induction of fibronectin adhesins in quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin or by sigma B transcription factor activity is mediated by two separate pathways. Antimicrob. Agents Chemother. 49:916-924.
23. Li, Y., et al. 2007. dnaB and dnaI temperature-sensitive mutants of Staphylococcus aureus: evidence for involvement of DnaB and DnaI in synchrony regulation of chromosome replication. Microbiology 153:3370-3379. (Pubitemid 47629542)
24. Lucet, J. C., et al. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
25. Luria, S. E., and M. Delbruck. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491-511.
26. Majcherczyk, P. A., T. McKenna, P. Moreillon, and P. Vaudaux. 2006. The discriminatory power of MALDI-TOF mass spectrometry to differentiate between isogenic teicoplanin-susceptible and teicoplanin-resistant strains of methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 255:233-239.
27. Malik, M., X. Zhao, and K. Drlica. 2006. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:810-825.
28. Mesak, L. R., and J. Davies. 2009. Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus. Res. Microbiol. 160:785-791.
29. Mesak, L. R., V. Miao, and J. Davies. 2008. Effects of subinhibitory concentrations of antibiotics on SOS and DNA repair gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3394-3397.
30. Michel, B., et al. 2001. Rescue of arrested replication forks by homologous recombination. Proc. Natl. Acad. Sci. U. S. A. 98:8181-8188.
31. Michel, B., G. Grompone, M. J. Flores, and V. Bidnenko. 2004. Multiple pathways process stalled replication forks. Proc. Natl. Acad. Sci. U. S. A. 101:12783-12788.
32. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
33. Novick, R. P., G. E. Christie, and J. R. Penades. 2010. The phage-related chromosomal islands of Gram-positive bacteria. Nat. Rev. Microbiol. 8:541-551.
34. O'Neill, A., et al. 2000. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 44:3163-3166.
35. O'Neill, A. J., and I. Chopra. 2002. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J. Antimicrob. Chemother. 50:161-169.
36. O'Neill, A. J., J. H. Cove, and I. Chopra. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J. Antimicrob. Chemother. 47:647-650.
37. O'Neill, A. J., T. Huovinen, C. W. Fishwick, and I. Chopra. 2006. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob. Agents Chemother. 50:298-309.
38. Prunier, A. L., and R. Leclercq. 2005. Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus. J. Bacteriol. 187:3455-3464. (Pubitemid 40628701)
39. Prunier, A. L., et al. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 187:1709-1716.
40. Renzoni, A., et al. 2006. Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:3048-3061.
41. Schaaff, F., G. Bierbaum, N. Baumert, P. Bartmann, and H. G. Sahl. 2003. Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int. J. Med. Microbiol. 293:427-435.
42. Shea, M. E., and H. Hiasa. 2003. The RuvAB branch migration complex can displace topoisomerase IV·quinolone·DNA ternary complexes. J. Biol. Chem. 278:48485-48490.
43. Ubeda, C., et al. 2005. Antibiotic-induced SOS response promotes horizontal dissemination of pathogenicity island-encoded virulence factors in staphylococci. Mol. Microbiol. 56:836-844.
44. Wichelhaus, T. A., et al. 2002. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:3381-3385.
45. Wichelhaus, T. A., V. Schafer, V. Brade, and B. Boddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816.